- Acorda Therapeutics, Inc. stock price today and history
Acorda Therapeutics, Inc. (ACOR) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Acorda Therapeutics, Inc. stock price
Acorda Therapeutics, Inc. latest news:
Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors
Shares of biotech Acorda Therapeutics Inc. surged 20% in premarket trade Friday, after media reports that Biogen Inc. and others are eyeing the company as a possible takeover target. The speculation has been swirling for more than a week. On Thursday, the company offered preliminary guidance for 2017 sales of $542 million, an increase of approximately 10% from 2016. The FactSet consensus is for sales of $568 million. Chief Executive Ron Cohen said he expects 2018 to be a transformative year and for the company to achieve approval and launch its Inbrija investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson's disease taking carbidopa/levodopa. Shares have gained 21% in the last 12 months, while the S&P 500 has gained about 24%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Acorda Therapeutics reportedly exploring potential sale
Investors in August had called for the company to explore a sale, after a judge in March struck down key patents of its MS drug Ampyra.
BRIEF-Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources
* ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES
Source text - http://on.wsj.com/2Ay49BA
Further company coverage:
Acorda Stock Up Despite Phase III Trial on Tozadenant Stops
Acorda Therapeutics Inc ACOR announced that it has decided to immediately discontinue the phase III study on one of its lead Parkinson s disease PD candidates tozadenant The decision was based on some serious safety issues reported last week observed in the study Shares of
Acorda Therapeutics Gets Crushed After Halting Parkinson’s Trial
BRIEF-Acorda provides update on tozadenant development program
Acorda Therapeutics Inc(ACOR): * Provides update on tozadenant development program.
Actions Semiconductor Co., Ltd.ACTS
Active Power, Inc.ACPW
Activision Blizzard, IncATVI
Acura Pharmaceuticals, Inc.ACUR
Adamas Pharmaceuticals, Inc.ADMS
Adamis Pharmaceuticals CorporationADMP
Adaptimmune Therapeutics plcADAP
Addus HomeCare CorporationADUS